SCH 58500
Alternative Names: p53 gene therapy - Schering-Plough; rAd/p53 - Schering-Plough; raDP-53 SCH 58500Latest Information Update: 25 Sep 2021
At a glance
- Originator Merck & Co; Schering-Plough
- Developer Merck & Co; Ore Pharmaceuticals
- Class Antineoplastics; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bladder cancer; Fallopian tube cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer
Most Recent Events
- 09 Jul 2014 Discontinued - Phase-I for Bladder cancer in USA (unspecified route)
- 09 Jul 2014 Discontinued - Phase-I for Fallopian tube cancer in USA (Intraperitoneal)
- 09 Jul 2014 Discontinued - Phase-I for Head and neck cancer in USA (Intratumoural)